BLLN — BillionToOne, Inc. Class A Common Stock Stock Price, Chart & AI Report

Neutral Aug 28, 2026 • 17:12 UTC The Motley Fool • Robert Izquierdo

BillionToOne's Co-Founder Sells 10,000 Shares for $1 Million

David Tsao, co-founder and CTO of BillionToOne, sold 10,000 shares for $1 million on August 25, 2026, through a pre-planned Rule 10b5-1 trading arrangement. The sale occurred after the stock declined from a 52-week high of $150.44, but Tsao retains 580,000 stock options, maintaining significant equity alignment with the company. Despite the recent share price drop following Q2 earnings, BillionToOne reported strong 64% year-over-year revenue growth.

BLLN insider trading stock sale molecular diagnostics Rule 10b5-1 trading plan equity stake prenatal screening precision diagnostics

Sentiment note

The insider sale is non-discretionary and pre-planned, so it doesn't reflect negative sentiment about the company. The CTO retains substantial equity (580,000 options), indicating confidence. However, the stock recently declined from highs and the sale timing coincides with post-earnings weakness. The company shows strong operational performance (64% YoY revenue growth) offsetting valuation concerns.

Positive Nov 7, 2025 • 21:05 UTC Benzinga • Globe Newswire

BillionToOne Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

BillionToOne, a molecular diagnostics company, successfully completed its initial public offering (IPO) on the Nasdaq Global Select Market, raising approximately $314.0 million by selling 5,233,765 shares of Class A common stock at $60.00 per share.

BLLN PIPR IPO molecular diagnostics Nasdaq public offering

Sentiment note

Successfully completed an upsized IPO, raising significant capital ($314.0 million), which indicates strong investor confidence and potential for future growth in molecular diagnostics technology